-
Views
-
Cite
Cite
Harshani Jayawardena-Thabrew, Adilia Warris, The PASOAP Group, Laura Ferreras-Antolin, Nystatin is commonly prescribed as prophylaxis in children beyond the neonatal age, Medical Mycology, Volume 61, Issue 1, January 2023, myac097, https://doi.org/10.1093/mmy/myac097
- Share Icon Share
Abstract
The indications for nystatin as prophylaxis or treatment are limited. In the PASOAP (Pediatric Antifungal Stewardship Optimizing Antifungal Prescription) study, high use of nystatin in hospitalized children beyond the neonatal age was observed. In this report, we present the data on nystatin use in infants and children ≥ 3 months who participated in the PASOAP study. Nystatin was prescribed mainly for prophylaxis. Congenital heart disease, cystic fibrosis, and chronic renal disease were the most commonly reported conditions in children receiving prophylactic nystatin. There is sparse evidence supporting the use of nystatin prophylaxis beyond neonates; trials in specific pediatric patient groups are required.
Lay Summary
The topical antifungal nystatin has not many indications. Prophylaxis of invasive candidiasis in very low birth weight neonates is one of them. In our study, we found that nystatin prophylaxis was used frequently beyond this specific neonatal group. Stronger evidence justifying its use is required.